Role of community pharmacists in cardiovascular diseases-related health promotion and dyslipidemia management in Malaysia: A nationwide cross-sectional study
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0290883 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Farhana Fakhira Ismail und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Quality Management of Medicine, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Community Pharmacy Services, Dyslipidemias. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cardiovascular disease (CVD) is a leading cause of death and disability worldwide, imposing a significant burden on patients and healthcare systems. The role of pharmacists in reducing cardiovascular disease (CVD) is pivotal as they play an essential part in the healthcare team, particularly in medication management and patient education. Pharmacists are well-positioned to contribute to the prevention and control of CVD through various roles, including medication management and patient education. This study aims to investigate the current involvement of community pharmacists in Malaysia, specifically in cardiovascular diseases-related health promotion activities and dyslipidemia management, including their perceived barriers.
Method
This cross-sectional survey was conducted among community pharmacists in all 14 states of Malaysia between November 2021 and July 2022. The self-administered survey was shared to relevant groups through various social media platforms.
Results
A total of 312 community pharmacists were involved in the survey. Majority of the respondents were females (66%), with a mean age (SD) of 32.9 (8.4) years. Most of the respondents showed satisfactory practice for patient counselling, but improvements are needed particularly in risk assessment and collaborative care aspect. Most of them expressed their interest for dyslipidemia management training (89.4%). Lack of access to medical records (71.2%) and lack of CVD-related educational materials (70.8%) were the two main perceived barriers identified.
Conclusion
Community pharmacists in Malaysia provide a satisfactory role in the provision of cardiovascular disease-related health promotion activities, especially in providing patient counselling. Strengthening collaborative care is essential for providing comprehensive and patient-centered intervention in dyslipidemia management. This requires ongoing efforts to address and overcome existing barriers for effective teamwork and coordination among healthcare professionals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Centre for Quality Management of Medicine, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA, Selangor, Malaysia.
- Department of Community and Pharmacy Practice, Faculty of Pharmacy, University of Cyberjaya, Cyberjaya, Selangor, Malaysia.
ORCID-Profile: Adyani Md Redzuan
Zitieren
APA
Ismail, F. F., Md Redzuan, A., Chong, W. W., & Ahmad Nizaruddin, M. (2023). Role of community pharmacists in cardiovascular diseases-related health promotion and dyslipidemia management in Malaysia: A nationwide cross-sectional study. PLOS ONE. https://doi.org/10.1371/journal.pone.0290883
Vancouver
Ismail FF, Md Redzuan A, Chong WW, Ahmad Nizaruddin M. Role of community pharmacists in cardiovascular diseases-related health promotion and dyslipidemia management in Malaysia: A nationwide cross-sectional study. PLOS ONE. 2023. doi:10.1371/journal.pone.0290883
BibTeX
@article{Ismail2023,
author = {Ismail, Farhana Fakhira and Md Redzuan, Adyani and Chong, Wei Wen and Ahmad Nizaruddin, Mariani},
title = {Role of community pharmacists in cardiovascular diseases-related health promotion and dyslipidemia management in Malaysia: A nationwide cross-sectional study},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0290883}
}
EUVIMED